During Harout’s nearly three decades as a global bio-pharmaceutical leader, he has built a reputation as an effective leader, building high-impact teams and delivering sustainable results.

He has launched and worked on numerous hematology/oncology assets and has provided strategic counsel on healthcare investments – all with patients in need of new treatments as his inspiration.

Harout’s educational background in science and business laid the foundation for his career. He holds a B.S. in Biology from the Lebanese American University, as well as MBAs from Cornell University and Queen’s University-Canada, respectively.

Harout entered the pharma industry in pharma sales in Lebanon and subsequently transferred to Novartis Canada, which led to a progression of strategic and operational roles with increasing leadership responsibility during his 17-year tenure. He served as global lead for Gleevec, SVP and global head for Ribociclib, and was VP & Franchise Head, US Hematology. Internationally, he has served as General Manager for the Nordic region, and Region Head for Middle East-North Africa at Novartis Oncology.

In 2017, Harout joined Ipsen as Vice President & Head of Specialty Care for an international region before becoming Executive Vice President and Chief Commercial Officer. In the EVP/CCO role, he was accountable for the company’s worldwide commercialization and portfolio strategy. Harout also briefly served as CEO of Immunomedics before its sale to Gilead, after which he became an independent advisor to private equity companies focused on healthcare investment.

Harout joined GlycoMimetics in August 2021 as President and CEO. The company discovered and is developing uproleselan, an investigational first-in-class E-selectin antagonist, currently advancing a Phase 3 study for treatment of acute myeloid leukemia.

In nearly two decades of pharmaceutical industry leadership, Gaetano has demonstrated a strong commitment to patient care, clinical and scientific research, and team leadership, as well as a passion for advancing treatment of hematological diseases.

His extensive experience encompasses multiple launches of hematologic therapies across diverse geographies including Europe, US and Americas, as well as Asia/Pacific. Gaetano led the US launch of midostaurin, a Flt-3 kinase inhibitor for acute myeloid leukemia. An accomplished medical affairs professional, he has held Global, US and European hematology and oncology executive roles for BMS, Novartis, GSK, and Amgen.

He received his medical degree and hematology board certification from the University of Palermo and his master’s degree in general management from the SDA Bocconi School of Management in Milan. Gaetano has broad clinical experience treating patients with hematologic diseases and solid tumors, as well as thrombosis and hemostasis. He has served as an investigator/sub-investigator across multiple clinical trials.

Lisa is passionate about bringing safer, more effective oncology drugs to cancer patients, which she currently does as Vice President of Regulatory Affairs at GlycoMimetics. Lisa joined GlycoMimetics in November 2021 with nearly 30 years of extensive Regulatory Affairs experience at large pharma and small biotech companies across multiple solid and liquid tumor types, including acute myeloid leukemia (AML).

Well-versed in regulatory strategy and agency interactions, Lisa has successfully led programs requiring complex dialogue with both the US Food and Drug Administration and international authorities. Her career is hallmarked by multiple product registrations and approvals. Most notably, while Vice President of Regulatory Affairs at Celator Pharmaceuticals, she directed activities surrounding the submission of an NDA for Vyxeos, which led to its approval as first therapeutic in over 40 years to improve survival for high-risk AML patients.

Lisa holds undergraduate and master’s degrees in biology from Eastern Michigan University, earned her Ph.D. from the University of Toledo, and was a postdoctoral fellow at the University of Michigan.

As General Counsel and Company Secretary of GlycoMimetics, Christian provides legal and strategic business support to the Board, senior management and all functional areas and serves as the company's compliance officer and data protection officer. In all his responsibilities, Christian aims to provide proactive and pragmatic solutions, while encouraging and empowering others to realize their goals.

Christian joined GlycoMimetics in April 2019 after more than 15 years of in-house experience at several public pharmaceutical and biotechnology companies, including AstraZeneca/MedImmune, Emergent BioSolutions, Inc., and Guliford Pharmaceuticals. At these companies, he supported strategic initiatives, pipeline programs, complex corporate transactions and SEC filings, among other legal and compliance-related responsibilities. Before joining the biotechnology field, Christian was associate counsel at law firms in Chicago, Kansas City and Washington, D.C.

Christian earned his J.D. with honors from the Chicago-Kent College of Law and a bachelor of business administration degree from the University of Wisconsin-Madison.

Mr. Hahn has more than 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as executive director of finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly-traded specialty pharmaceutical company. Prior to Advancis, he was a senior accountant with Bering Truck Corporation. Mr. Hahn has worked with life science companies from early stages through product launch. He has been involved in multiple initial public offerings and has broad experience in developing strategic plans, creating business models, establishing accounting and auditing systems and ensuring Sarbanes-Oxley compliance. Currently, Mr. Hahn serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO), and also serves on the Securities and Exchange Commissions’ Advisory Committee on Small and Emerging Companies. He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

Martina is Vice President, Clinical Operations at GlycoMimetics. She joined the company in November 2010 and previously served as Senior Director, Clinical Programs and Director, Clinical Operations.

Martina has more than 25 years of Phase 1-3 experience in clinical pharmaceutical operations in academic, CRO and biotech settings, and across numerous therapeutic areas. In addition to more than 10 years working in hematology/oncology, she has experience in biodefense, cardiology, infectious disease, neurology, psychiatry, transplant and vaccines. She has worked across multiple solid and liquid tumor types, including acute myeloid leukemia. Before her clinical research career, Martina worked in the psychiatric field in direct patient care, specializing in the treatment of personality disorders.

Martina holds a B.A. in psychology from Stony Brook University and an M.A. in clinical psychology from Yeshiva University.

Stephanie joined GlycoMimetics in 2014. As the Vice President of Accounting, she oversees the company’s accounting and tax operations and manages SEC reporting.

She has more than 25 years’ experience in finance and accounting, working primarily for private and public life science companies. Before joining GlycoMimetics, Stephanie was Acting Chief Financial Officer at Vanda Pharmaceuticals, Inc., and held controller roles at Zyngenia Inc., and Avalon Pharmaceuticals.

A Certified Public Accountant, Stephanie is a member of the Maryland Association of Certified Public Accountants and the American Institute of CPAs.

Stephanie received a a B.S. degree in Business Administration from the University of Maryland, College Park.

Bruce joined GlycoMimetics in 2022 and has worldwide commercial responsibility for the GlycoMimetics pipeline.

Bruce has more than 25 years’ experience in the biopharma industry with a solid track record of leading multi-billion commercial franchises with responsibility for achieving commercialization, establishing novel capabilities, and improving profitability. He has successfully led product launches across a variety of disease areas, including breast, lung, kidney, melanoma and neuroendocrine tumors, as well as a wide range of hematologic malignancies and rare diseases. His direct launch experience includes Jakavi, Gleevec/Glivec, Rydapt, and Tasigna in hematology as well as Afinitor, Sandostatin/Sandostatin LAR, and Zometa in solid tumors.

Previously, Bruce was Executive Vice President and Chief Commercial Officer of the digital health company Cancer Expert Now, Inc. He helped lead the organization to national recognition by Inc. Magazine as one of the Top 500 fastest-growing small companies in America. He worked for 25 years at Novartis, where he held several executive global and regional roles, including Vice President and Global Franchise Head, Malignant Hematology and Vice President and Global Disease Leader, Leukemia Franchise. He has also worked for AbbVie, Sandoz and Memorial Sloan-Kettering Cancer Center.

Bruce received a bachelor’s degree in Microbiology from Miami University (Oxford, Ohio). His education includes graduate work at Columbia University in Biochemistry and Molecular Biology and at Rutgers University School of Management in Marketing and Finance.

A member of the GlycoMimetics management team since February 2023, Debora has extensive global and US commercial pharmaceutical and biotech experience, highlighted by more than 17 product launches, and in-depth knowledge of the hematology, oncology and rare disease therapeutic areas.

Before joining GlycoMimetics, Debora was Rare Disease, VP Franchise Head, for Ipsen. In that role, she hired a commercial team that would represent this new area of investment and focus for the company, developed and concluded the launch strategy and commercialization plans for palovarotene, and identified and developed new commercial opportunities.

Debora spent 16 years of her career at Novartis, where she developed professionally through roles of increasing responsibility in the hematology, oncology and rare disease therapeutic areas. Among those roles, she was Senior Marketing Director, U.S. Hematology, for which she led the team supporting the simultaneous Rydapt® launch in two indications (Acute Myeloid Leukemia and Advanced Systemic Mastocytosis); Executive Director, Global Hematology Franchise, for which she led and managed the launch preparation for a sickle cell disease product; and Executive Director, Rare Diseases, Global Solid Tumor Franchise.

In addition to a strong strategy skillset and the ability to navigate complex commercial scenarios, Debora has extensive experience leading multidisciplinary teams and a deep understanding of what it takes to bring products to market as well as pipeline management.

Debora holds a Bachelor of Science in Biomedicine from Mogi das Cruzes University, Brazil, as well as a post-graduate degree in marketing and MBA in marketing administration from ESPM Marketing College in Sao Paulo, Brazil. She is fluent in English, Portuguese, and Spanish.

John, who joined GlycoMimetics in 2012 as Senior Director of Chemistry, manages the company's internal and external discovery chemistry initiatives and provides strategic guidance on drug candidate optimization.

He has nearly 30 years’ experience in drug discovery. John began his career at Neurogen Corporation where he assumed positions of increasing responsibility culminating in management of the Hits to Leads group. He then moved to H Lundbeck A/S where he served as Project Leader for several central nervous system-related programs.

John received a Ph.D. in Chemistry from Yale University, where his research focused on oligosaccharide synthesis – including the E-selectin ligand Sialyl-Lewis X. He earned a BS in Chemistry from the University of Illinois Urbana-Champaign.

Chinmaya is a global bio-pharma leader with a passion to bring innovative therapeutics to patients. For more than two decades, he has successfully assembled and led multi-functional teams that have consistently exceeded business objectives in dynamic situations by aligning people, objectives, priorities, and processes. He has effectively managed biotech start-ups, strategy, alliances, innovation, pre-clinical research, and commercial from early discovery to launch and in-line marketing across US, Europe, and Asia.

Most recently Chinmaya was the Entrepreneur-in-residence with Catena Biosciences, where he is appointed as a Director. As a Venture Partner with Social Impact Capital, he advised their early-stage biotech investments. Prior to that, he was a Founder CEO of CelluRx, a potential cell therapy spin-off of Saliogen Therapeutics. In 2019, Chinmaya joined the leadership team at Omega Therapeutics (a Flagship Pioneering Company) where he played a key role in defining the strategy, portfolio, innovation, and business development efforts from pre-Series A to IPO in 2021.

He also has expertise in business integration/acquisition, having led the US integration post-GSK Oncology acquisition and global commercial operations integration post-Alcon acquisition. He also has significant experience in leading high-impact enterprise-wide strategic projects at Novartis.

Chinmaya has profound business acumen in oncology/hematology therapeutics while leading major US launches in both hematology and solid tumors.

Chinmaya received MBAs from Warwick Business School, UK, and the Army Institute of Management Studies, India. He completed his undergraduate studies in Life Science with honors from Ravenshaw University, India.

Bryan joined GlycoMimetics in 2016 and is responsible for overseeing major project operations and implementing project management skills, tools and best practices across the company.

A Certified Project Management Professional and Project Management Institute member, Bryan has more than 23 years’ experience leading drug development projects and programs. He worked for more than 10 years at ICON Clinical Research, where he held several project management positions and gained experience on projects spanning a variety of compounds, indications and dosage forms. He was also Director, Project Management, at Rexahn Pharmaceuticals.

Bryan received a B.S. degree in Marine and Environmental Chemistry from the Florida Institute of Technology and an MBA from The Johns Hopkins University.

Dr. Rock worked for 16 years in biopharma roles of increasing responsibility before joining GlycoMimetics in 2022. Most recently he was Chief Medical Officer at Partner Therapeutics. Previously, at MacroGenics he led the program culminating in FDA approval of Margenza^TM. Dr. Rock has worked in biopharma on small molecules and biologics in all stages of development and marketing authorization. These agents include Busulfex^TM, Inqovi^®, Jynarque^®, Leukine^®, Margenza^TM, Nucala, and Sprycel^®, as well as investigational GNX-8, guadecitabine, lorigerlimab, the MAGE-A3 cancer vaccine, OPB-31121, OPB-51602, OPB-111077, retifanlimab, tebotelimab, and others not disclosed. Earlier, he worked for a year as a life sciences buyside analyst at Leerink Swann and Company and for 2 years as an FDA Medical Officer in oncology drug review. Dr. Rock holds a BA in Biology and Economics from Swarthmore College. He earned Ph.D. then MD degrees at Stanford before Internal Medicine residency at Brigham and Women’s Hospital and Medical Oncology fellowship at the University of Pennsylvania.

Throughout his career in pharmaceutical leadership, Shantha has been recognized as a dynamic and forward-thinking executive, who brings a patient-centric approach and an enterprise-wide perspective to drive development, approvals, and launch of life-changing medicines.

He has played a pivotal role in advancing more than 30 Investigational New Drug (IND) applications from initial stages through to clinical development, achieving Marketing Authorization, and has been key in the commercial launch of numerous drug products. His contributions have been crucial in enabling several drug development programs to secure Fast Track designation from the FDA.

He brings to GlycoMimetics nearly two decades of biopharmaceutical experience transitioning development-stage products into successful commercial launches. Most recently, he served as Senior Vice President, Global Pharmaceutical Operations (CMC) & Drug Development at CTI Biopharma (Acquired by SOBI). During this period, Dr. Tyavanagimatt achieved US NDA approval for VONJO® (pacritinib) and EU MAA approval for Pixuvri® (pixantrone). His leadership played a pivotal role in the rapid growth of CTI from $100M in enterprise value in 2016 to $1.78Bn in 2023.

Before CTI Biopharma, Shantha held the position of Senior Vice President, Drug Development & Manufacturing, where he spearheaded the development and manufacturing of range of drug candidates, culminating in the US NDA approval of TPOXX® (tecovirimat) both capsule and IV formulations. This achievement led to a product purchase exceeding $400Mn from the US government.

Shantha holds a Bachelor of Pharmacy from the Government College of Pharmacy, Bangalore University and a Master of Pharmacy, Pharmaceutics & Pharmacokinetics from the College of Pharmaceutical Sciences, Manipal. His Ph.D. in Pharmaceutical Technology is from Maharaja Sayajirao University, and he was a postdoctoral fellow in Pharmaceutics- Drug Delivery at University of Utah. He currently resides in Washington state.